. 2014 Aug 29;47(2):266–273. doi: 10.4143/crt.2013.158

Table 3.

Hazard ratio of survival by pretreatment characteristics (GEM-X arm vs. GEM-T arm)

Factor	No.	PFS			OS
Factor	No.	HR	95% CI	p-value	HR	95% CI	p-value
GEM-X:GEM-T	80	0.36	0.20-0.64	0.001^a)	0.52	0.28-0.96	0.037^a)
Age (yr)
≤65	46	0.36	0.16-0.81	0.013^a)	0.33	0.14-0.76	0.01^a)
>65	34	0.24	0.08-0.68	0.007^a)	0.94	0.35-2.48	0.903
ECOG performance status
0 or 1	75	0.38	0.21-0.70	0.002^a)	0.57	0.30-1.10	0.095
2	5	0.01	0.00-153.5	0.36	0.01	0.00-153.5	0.36
Disease status
Locally advanced	25	0.25	0.07-0.85	0.027^a)	0.43	0.13-1.46	0.179
Distant metastatic	43	0.36	0.16-0.77	0.009^a)	0.45	0.19-1.07	0.074
CA 19-9 (U/mL)
≤500	40	0.27	0.11-0.62	0.002^a)	0.6	0.24-1.52	0.285
>500	39	0.58	0.26-1.28	0.182	0.45	0.19-1.05	0.067

GEM-X, gemcitabine plus capecitabine; GEM-T, gemcitabine plus erlotinib; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; CA 19-9, carbohydrate antigen 19-9.

^a)

p<0.05.